Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment
Open accessThe DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Abstract
Invasive Candida infections remain an important cause of morbidity and mortality, especially in hospitalized and immunocompromised or critically ill patients. A limited number of antifungal agents from only a few drug classes are available to treat patients with these serious infections. Resistance can be either intrinsic or acquired. Resistance mechanisms are not exchanged between Candida; thus, acquired resistance either emerges in response to an antifungal selection pressure in the individual patient or, more rarely, occur due to horizontal transmission of resistant strains between patients. Although multidrug resistance is uncommon, increasing reports of multidrug resistance to the azoles, echinocandins, and polyenes have occurred in several Candida species, most notably Candida glabrata and more recently Candida auris. Drivers are overall antifungal use, subtherapeutic drug levels at sites of infection/colonization, drug sequestration in the biofilm matrix, and, in the setting of outbreaks, suboptimal infection control. Moreover, recent research suggests that DNA mismatch repair gene mutations may facilitate acquisition of resistance mutations in C. glabrata specifically. Diagnosis of antifungal-resistant Candida infections is critical to the successful management of patients with these infections. Reduction of unnecessary use of antifungals via antifungal stewardship is critical to limit multidrug resistance emergence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-resistant fungal infections are emerging as an important clinical problem1,2.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [1]
In the citing paper
“C. auris appears to rapidly acquire resistance or tolerance to echinocandins as well polyenes1,42, leaving few, if any, treatment options.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [1]
In the citing paper
“The genes listed (in Supplementary Data) might be identified as C. albicans specific MDR genes [46], as very little overlap is displayed between these elements and the MDR genes described in S. cerevisiae [46,47].”
From Known Antimicrobials Versus Nortriptyline in Candida albicans: Repositioning an Old Drug for New Targets (2020) · cites this paper as [46]
In the citing paper
“Indeed, expression of these ATP binding cassette transporters (ABC) is often higher in resistant clinical isolates [46,48].”
From Known Antimicrobials Versus Nortriptyline in Candida albicans: Repositioning an Old Drug for New Targets (2020) · cites this paper as [46]
In the citing paper
“In contrast, biofilms of C. glabrata and C. tropicalis do not possess such persister cells [13,43].”
From Candida glabrata: pathogenicity and resistance mechanisms for adaptation and survival (2021) · cites this paper as [43]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449 · cited 2×
“Similar findings were reported at other US hospitals, and a CDC survey showed rates of 3.1%–3.6% from 4 US cities in varying geographic regions [32].”
BackgroundInfluentialMultistate point-prevalence survey of health care-associated infections
Magill, S. S., Edwards, J. R., Bamberg, W., Beldavs, Z. G., Dumyati, G., Kainer, M. A., Lynfield, R., Maloney, M., McAllister-Hollod, L., Nadle, J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1306801 · Cited by 3,931
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 9×
“Prevention strategies to limit development of MDR and XDR infections are critical.”
BackgroundInfluentialKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315
Self-citationPappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ1194 · Cited by 1,298
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Self-citationWingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937 · cited 1×
“glabrata) in many regions of the world and in specific patient populations such as in transplantation, where azole use is widespread and continued for long-term for prophylaxis and therapy of infection [19, 20].”
BackgroundAlexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778 · cited 2×
“A report from one US medical center demonstrated that over a 10 year-period, echinocandin resistance rose from 2%–3% to >13% in 2009–2010 [34].”
BackgroundFirst hospital outbreak of the globally emerging Candida auris in a European hospital
Schelenz, S., Hagen, F., Rhodes, J. L., Abdolrasouli, A., Chowdhary, A., Hall, A., Ryan, L., Shackleton, J., Trimlett, R., Meis, J. F., et al. (2016) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-016-0132-5 · Cited by 768
Kathuria, S., Singh, P. K., Sharma, C., Prakash, A., Masih, A., Kumar, A., Meis, J. F., & Chowdhary, A. (2015) · Journal of Clinical Microbiology · doi:10.1128/jcm.00367-15 · Cited by 532
Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., Che, D., & Dromer, F. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.140087 · Cited by 426
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Sanglard, D. (2016) · Frontiers in Medicine · doi:10.3389/fmed.2016.00011 · Cited by 416
Coste, A. T., Karababa, M., Ischer, F., Bille, J., & Sanglard, D. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.6.1639-1652.2004 · Cited by 407
Echinocandin resistance in Candida.
Perlin, D. S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ791 · Cited by 374 · cited 3×
“albicans infection, experimental animal data suggest that some less critical FKS mutations may be associated with higher response rates with higher doses of therapy, but clinical correlation of those data are lacking [36, 39].”
BackgroundMultidrug-resistant endemic clonal strain of Candida auris in India
Chowdhary, A., Anil Kumar, V., Sharma, C., Prakash, A., Agarwal, K., Babu, R., Dinesh, K. R., Karim, S., Singh, S. K., Hagen, F., et al. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2027-1 · Cited by 373 · cited 2×
“Recent reports have documented infection throughout the world, including the United States, most typically associated with healthcare-associated infections including transmission in healthcare facilities [16, 24, 26–29].”
BackgroundCleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, S. R., Magill, S. S., Derado, G., Park, B. J., & Chiller, T. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis697 · Cited by 366
Lortholary, O., Desnos-Ollivier, M., Sitbon, K., Fontanet, A., Bretagne, S., & Dromer, F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01128-10 · Cited by 362
Garcia-Effron, G., Katiyar, S. K., Park, S., Edlind, T. D., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00262-08 · Cited by 323
Fitness Trade-offs Restrict the Evolution of Resistance to Amphotericin B
Vincent, B. M., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., & Lindquist, S. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001692 · Cited by 322 · cited 2×
“albicans and Candida dubliniensis [45, 62, 64, 65].”
BackgroundMechanisms of echinocandin antifungal drug resistance
Perlin, D. S. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12831 · Cited by 313
Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., Kemble, S. K., Pacilli, M., Black, S. R., Landon, E., et al. (2016) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6544e1 · Cited by 302
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 1×
“The pleiotropic class of the ATP binding cassette (ABC) transporters (PDR) include the major azole drug transporters CDR1, CDR2 , and specifically for C. glabrata also the CgSNQ2 , and confer panazole resistance [40–42, 53].”
BackgroundMorio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.11.006 · Cited by 279
Dunkel, N., Blaß, J., Rogers, P. D., & Morschhäuser, J. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06309.x · Cited by 278
Healey, K. R., Zhao, Y., Perez, W. B., Lockhart, S. R., Sobel, J. D., Farmakiotis, D., Kontoyiannis, D. P., Sanglard, D., Taj-Aldeen, S. J., Alexander, B. D., et al. (2016) · Nature Communications · doi:10.1038/ncomms11128 · Cited by 276 · cited 1×
“glabrata facilitate rapid acquisition of fluconazole, echinocandin, and amphotericin B resistance [70].”
BackgroundMoran, G. P., Sullivan, D. J., Henman, M. C., McCreary, C. E., Harrington, B. J., Shanley, D. B., & Coleman, D. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.617 · Cited by 271
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269 · cited 1×
“This is particularly true in patients requiring longterm treatment and in those receiving antifungal prophylaxis, highlighting the importance of antifungal stewardship [6, 7].”
BackgroundInvasive Infections with Multidrug-Resistant Yeast Candida auris , Colombia
Morales-López, S. E., Parra-Giraldo, C. M., Ceballos-Garzón, A., Martínez, H. P., Rodríguez, G. J., Álvarez-Moreno, C. A., & Rodríguez, J. Y. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2301.161497 · Cited by 243
Dunkel, N., Liu, T. T., Barker, K. S., Homayouni, R., Morschhäuser, J., & Rogers, P. D. (2008) · Eukaryotic Cell · doi:10.1128/ec.00103-08 · Cited by 236
Vermitsky, J., Earhart, K. D., Smith, W. L., Homayouni, R., Edlind, T. D., & Rogers, P. D. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05235.x · Cited by 233
Pham, C. D., Iqbal, N., Bolden, C. B., Kuykendall, R. J., Harrison, L. H., Farley, M. M., Schaffner, W., Beldavs, Z. G., Chiller, T. M., Park, B. J., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03255-14 · Cited by 231
Multidrug-resistant Candida auris: ‘New kid on the block’ in hospital-associated infections?
Chowdhary, A., Voss, A., & Meis, J. F. (2016) · Journal of Hospital Infection · doi:10.1016/j.jhin.2016.08.004 · Cited by 214 · cited 4×
“A few strains (7%) have elevated MICs to the echinocandins as well [23].”
BackgroundInfluentialNett, J. E., Crawford, K., Marchillo, K., & Andes, D. R. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00227-10 · Cited by 207 · cited 1×
“but also provides an environment of lower exposure that may facilitate selection of acquired resistance [74].”
BackgroundSharma, C., Kumar, N., Pandey, R., Meis, J. F., & Chowdhary, A. (2016) · New Microbes and New Infections · doi:10.1016/j.nmni.2016.07.003 · Cited by 202
Vallabhaneni, S., Cleveland, A. A., Farley, M. M., Harrison, L. H., Schaffner, W., Beldavs, Z. G., Derado, G., Pham, C. D., Lockhart, S. R., & Smith, R. M. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv163 · Cited by 187
Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with Fungemia
Arendrup, M. C., Sulim, S., Holm, A., Nielsen, L., Nielsen, S. D., Knudsen, J. D., Drenck, N. E., Christensen, J. J., & Johansen, H. K. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.00179-11 · Cited by 178
Self-citationFKS Mutant Candida glabrata: Risk Factors and Outcomes in Patients With Candidemia
Beyda, N. D., John, J., Kilic, A., Alam, M. J., Lasco, T. M., & Garey, K. W. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu407 · Cited by 174
Identification and Characterization of Four Azole-Resistant erg3 Mutants of Candida albicans
Martel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Rolley, N., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00348-10 · Cited by 168 · cited 2×
“albicans and Candida dubliniensis [45, 62, 64, 65].”
BackgroundPrakash, A., Sharma, C., Singh, A., Kumar Singh, P., Kumar, A., Hagen, F., Govender, N. P., Colombo, A. L., Meis, J. F., & Chowdhary, A. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.022 · Cited by 167
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., & White, T. C. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.10.2584 · Cited by 166 · cited 1×
“In these patients resistance can be stable or transient, in response to azole treatment [8].”
BackgroundMartel, C. M., Parker, J. E., Bader, O., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-10 · Cited by 165
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 160
Self-citationCastanheira, M., Messer, S. A., Rhomberg, P. R., & Pfaller, M. A. (2016) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2016.02.009 · Cited by 159 · cited 1×
“%) of echinocandin resistance [31].”
Nosocomial fungemia by Candida auris: First four reported cases in continental Europe
Ruiz Gaitán, A. C., Moret, A., López Hontangas, J. L., Molina, J. M., Aleixandre López, A. I., Cabezas, A. H., Mollar Maseres, J., Arcas, R. C., Gómez Ruiz, M. D., Chiveli, M. Á., et al. (2017) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2016.11.002 · Cited by 158
Morio, F., Pagniez, F., Lacroix, C., Miegeville, M., & Le Pape, P. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks186 · Cited by 120 · cited 1×
“albicans and Candida dubliniensis [45, 62, 64, 65].”
Abdominal candidiasis is a hidden reservoir of echinocandin resistance
Shields, R. K., Nguyen, M. H., Press, E. G., & Clancy, C. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04134-14 · Cited by 118 · cited 1×
“Second, Jensen et al reported a high rate of echinocandin-resistant C. glabrata in the oral microflora after candidemia treatment with ≥ 7 days of echinocandins, and Shields et al reported a high prevalence among C. glabrata iso-lates from abdominal candidiasis [72, 73].”
BackgroundVandeputte, P., Tronchin, G., Larcher, G., Ernoult, E., Bergès, T., Chabasse, D., & Bouchara, J.-P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00423-08 · Cited by 117
Arendrup, M. C., Perlin, D. S., Jensen, R. H., Howard, S. J., Goodwin, J., & Hope, W. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06369-11 · Cited by 117 · cited 5×
“albicans isolate with heterologous Fks1pR647R/G and P649P/L double mutations [56, 57].”
BackgroundInfluentialSelf-citationRevankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Dib, O. P., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1996) · Journal of Infectious Diseases · doi:10.1093/infdis/174.4.821 · Cited by 109
Self-citationChapeland-Leclerc, F., Hennequin, C., Papon, N., Noël, T., Girard, A., Socié, G., Ribaud, P., & Lacroix, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01138-09 · Cited by 104
Lewis, J. S., Wiederhold, N. P., Wickes, B. L., Patterson, T. F., & Jorgensen, J. H. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01144-13 · Cited by 101
Self-citationChanges in susceptibility to posaconazole in clinical isolates of Candida albicans
Li, X. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh027 · Cited by 96
Jensen, R. H., Astvad, K. M. T., Silva, L. V., Sanglard, D., Jørgensen, R., Nielsen, K. F., Mathiasen, E. G., Doroudian, G., Perlin, D. S., & Arendrup, M. C. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv140 · Cited by 95 · cited 1×
“albicans from a patient with mucosal infection over a 5-year period [49], and azole, flucytosine, and echinocandin resistance was acquired in C.”
BackgroundSelf-citationHull, C. M., Bader, O., Parker, J. E., Weig, M., Gross, U., Warrilow, A. G. S., Kelly, D. E., & Kelly, S. L. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01145-12 · Cited by 90
Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
Asner, S. A., Giulieri, S., Diezi, M., Marchetti, O., & Sanglard, D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02204-15 · Cited by 82
Sanglard, D., & Coste, A. T. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02157-15 · Cited by 77
Jensen, R. H., Johansen, H. K., Søes, L. M., Lemming, L. E., Rosenvinge, F. S., Nielsen, L., Olesen, B., Kristensen, L., Dzajic, E., Astvad, K. M. T., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01763-15 · Cited by 77
Self-citationDellière, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., Lecefel, C., Touratier, S., Desnos-Ollivier, M., Perlin, D. S., et al. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.02038 · Cited by 75
Rapid Development of Candida krusei Echinocandin Resistance during Caspofungin Therapy
Forastiero, A., Garcia-Gil, V., Rivero-Menendez, O., Garcia-Rubio, R., Monteiro, M. C., Alastruey-Izquierdo, A., Jordan, R., Agorio, I., & Mellado, E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01005-15 · Cited by 68
Lackner, M., Tscherner, M., Schaller, M., Kuchler, K., Mair, C., Sartori, B., Istel, F., Arendrup, M. C., & Lass-Flörl, C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00123-14 · Cited by 67 · cited 2×
“In the vast majority of cases only a single mutation is responsible, although rare cases several alterations are found [57].”
BackgroundSelf-citationMolecular Mechanisms of Itraconazole Resistance in Candida dubliniensis
Pinjon, E., Moran, G. P., Jackson, C. J., Kelly, S. L., Sanglard, D., Coleman, D. C., & Sullivan, D. J. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2424-2437.2003 · Cited by 65
Erbs, P., Exinger, F., & Jund, R. (1997) · Current Genetics · doi:10.1007/s002940050169 · Cited by 63
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 60
Self-citationRapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin
Fekkar, A., Meyer, I., Brossas, J. Y., Dannaoui, E., Palous, M., Uzunov, M., Nguyen, S., Leblond, V., Mazier, D., & Datry, A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02037-12 · Cited by 56 · cited 1×
“Other Candida species have also been reported to acquire MDR after antifungal exposure, including C. albicans and others, such as Candida kefyr and Candida lusitaniae [35–38].”
BackgroundTumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., & Posteraro, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn381 · Cited by 53
Costa, C., Ponte, A., Pais, P., Santos, R., Cavalheiro, M., Yaguchi, T., Chibana, H., & Teixeira, M. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0135110 · Cited by 46 · cited 1×
“arginine homeostasis, cell wall remodeling, and the aquaglyceroporins of the Fps family [59].”
BackgroundEUCAST Technical Note on Candida and micafungin, anidulafungin and fluconazole
Cavling Arendrup, M., Cuenca‐Estrella, M., Lass‐Flörl, C., Hope, W. W., & The European Committee on Antimicrobial Susceptibility Testing – Subcommittee on Antifungal Susceptibility Testing (EUCAST‐AFST) (2014) · Mycoses · doi:10.1111/myc.12170 · Cited by 43
Self-citationBen-Ami, R., & Kontoyiannis, D. P. (2012) · Virulence · doi:10.4161/viru.3.1.18886 · Cited by 39 · cited 1×
“species that possess no intrinsic resistance is rare, as in general it requires acquisition of several resistance mechanisms and these often come at a fitness cost [62, 63].”
BackgroundCandida glabrata sepsis secondary to oral colonization in bone marrow transplantation
Redding, S. W., Marr, K. A., Kirkpatrick, W. R., Coco, B. J., & Patterson, T. F. (2004) · Medical Mycology · doi:10.1080/13693780410001731574 · Cited by 38
Self-citationCandida kruseisepsis secondary to oral colonization in a hemopoietic stem cell transplant recipient
Westbrook, S. D., Kirkpatrick, W. R., Freytes, C. O., Toro, J. J., Bernardo, S. M., Patterson, T. F., Redding, S. W., & Lee, S. A. (2007) · Medical Mycology · doi:10.1080/13693780601164306 · Cited by 31
Self-citationBordallo-Cardona, M. Á., Escribano, P., de la Pedrosa, E. G. G., Marcos-Zambrano, L. J., Cantón, R., Bouza, E., & Guinea, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01542-16 · Cited by 31
Cheng, J.-W., Yu, S.-Y., Xiao, M., Wang, H., Kudinha, T., Kong, F., & Xu, Y. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.00938-16 · Cited by 29
Echinocandin Failure Case Due to a Previously Unreported FKS1 Mutation in Candida krusei
Jensen, R. H., Justesen, U. S., Rewes, A., Perlin, D. S., & Arendrup, M. C. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02367-14 · Cited by 28
Self-citationCharlier, C., El Sissy, C., Bachelier-Bassi, S., Scemla, A., Quesne, G., Sitterlé, E., Legendre, C., Lortholary, O., & Bougnoux, M.-E. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02265-15 · Cited by 26
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute, 2012, Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. Document M27-S4
Cited by
Pfaller, M. A., Diekema, D. J., Turnidge, J. D., Castanheira, M., & Jones, R. N. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy358 · Cited by 825
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Candidiasis and Mechanisms of Antifungal Resistance
Bhattacharya, S., Sae-Tia, S., & Fries, B. C. (2020) · Antibiotics · doi:10.3390/antibiotics9060312 · Cited by 474
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Fungal infections in humans: the silent crisis
Kainz, K., Bauer, M. A., Madeo, F., & Carmona-Gutierrez, D. (2020) · Microbial Cell · doi:10.15698/mic2020.06.718 · Cited by 369
Metadata
- Authors
- Arendrup, M. C., & Patterson, T. F.
- Affiliations
- Statens Serum Institut (DK)
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Arendrup, Maiken Cavling
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-08-15
- Volume
- 216
- Issue
- suppl_3
- Pages
- S445-S451
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2750959598
- Cited by
- 707
- References
- 74
- Citations by year
- 2026: 90 · 2025: 82 · 2024: 93 · 2023: 78 · 2022: 92 · 2021: 96 · 2020: 74 · 2019: 62 · 2018: 37 · 2017: 2
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- invasive candidiasis, antifungal resistance, Candida glabrata, Candida auris, azole resistance, echinocandin resistance, polyene resistance, intrinsic resistance, acquired resistance, DNA mismatch repair, biofilm, antifungal stewardship, infection control, epidemiology of resistance
- MeSH terms
- Animals, Antifungal Agents, Azoles, Candida, Disease Models, Animal, Humans, Microbial Sensitivity Tests, Critical Illness, Drug Resistance, Multiple, Fungal, Candida glabrata, Echinocandins, Candidiasis, Invasive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.